---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-139145"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:50:46.113034+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Decoy Therapeutics regains Nasdaq minimum bid price compliance after reverse split

## Summary
- Nasdaq confirmed compliance on March 31, 2026; Common Stock bid price closed at $7.47 on March 20, 2026.
- Reverse stock split effective March 6, 2026, to cure bid price deficiency below $1.00.
- Company subject to Mandatory Panel Monitor until March 31, 2027; future non-compliance may trigger delisting.
- Hearings Panel granted exception until March 20, 2026; compliance achieved with 10 consecutive days above $1.00.

## SEC filing metadata
- accession: 0001193125-26-139145
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000119312526139145/0001193125-26-139145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000119312526139145/dcoy-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-139145
- JSON: https://secwatch.observer/filing/0001193125-26-139145.json
- Plain text: https://secwatch.observer/filing/0001193125-26-139145.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.